Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04918524
Other study ID # CTD with Pregnancy QiluH
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 11, 2018
Est. completion date December 31, 2026

Study information

Verified date November 2023
Source Qilu Hospital of Shandong University
Contact Qiang Shu, Dr.
Phone 0086-0531-82169654
Email shuqiang@sdu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Connective tissue disease (CTD) is a common group of autoimmune diseases, mainly including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) , and so on. APS is caused by autoimmune disorders that cause recurrent miscarriage, thrombosis, and thrombocytopenia, and often secondary to connective tissue diseases such as SLE. Undifferentiated connective tissue disease (UCTD) is currently considered to be an independent disease in the classification of CTD. And women of childbearing age who suffer UCTD is more common than that in other definite CTDs. Therefore, the impact of the disease flare and the influence of medicine on pregnancy and lactation are important for these patients who may suffer high-risk of abnormal pregnance.


Description:

Objective: To study the risk factors of poor pregnancy outcomes in CTD patients, and evaluate impact of different therapies on the maternal and fetal health. Methods: Our department and Shanghai Gothic Network Technology Co.Ltd. jointly established the chronic disease management of CTD patients during pregnancy and lactation by using Smart System of Disease Management (SSDM). With this platform, patients in pregnancy can consult with rheumatologists face to face and follow-up regularly. Follow-up: Consultation and followup will be scheduled every 4 weeks from confirmed pregnancy until delivery.


Recruitment information / eligibility

Status Recruiting
Enrollment 126
Est. completion date December 31, 2026
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: - Women who meet the following inclusion criteria will be eligible to participate in the study: 1. Age between 20-45 years; 2. Diagnosed with APS: patients meet the Sydney classification criteria; 3. Diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, antiphospholipid antibody(aPL), and non-criteria aPL (NC-aPL), with at least one symptoms or signs suggesting connective tissue disease(CTD) , while not fulfilling any classification criteria of a defined CTD. 4. Participate voluntarily in this study, willing to use medication and follow-up according to treatment plan, and sign informed consent. Exclusion Criteria: - Women who meet any of the following criteria will be excluded from the study: 1.Any known etiology of previous pregnancy loss: 1. Known paternal, maternal or embryo chromosome abnormality. 2. Maternal endocrine dysfunction: corpus luteal insufficiency; polycystic ovarian syndrome; premature ovarian failure (follicle stimulating hormone, FSH =20uU/L in follicular phase); 3. hyperprolactinemia; diabetes mellitus; other hypothalamic pituitary-adrenal axis abnormality 4. Maternal anatomical abnormality: uterine malformation; Asherman syndrome; cervical incompetence; uterine fibrosis more than 5 cm.Vaginal infection. 5. Any known severe cardiac, hepatic, renal, hematological or endocrinal diseases: 2. Any active infection: Active infection including V aricella zostervirus(VZV), human immunodeficiency virus (HIV), Human papillomavirus (HPV),syphilis or tuberculosis. 3. Allergic to prednisone, hydroxychloroquine, low-molecular-weight heparin or aspirin. 4.Disease history as follows: 1. Past history of digestive ulcers or upper gastrointestinal hemorrhage. 2. Past history of malignancy. 3. Past history of epilepsia or psychotic disorders. 5.Women have been diagnosed with Systemic lupus erythematosus 6. Women who disagree or cannot complete pregnancy and follow-up after delivery.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prednisone
5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
Hydroxychloroquine
100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
Aspirin
100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
low molecular weight heparin Enoxaparin
40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.

Locations

Country Name City State
China Qilu Hospital Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth rate Percentage of all patients that lead to live birth after 28 weeks of gestation After 28 weeks of gestation
Secondary Early fetal loss Spontaneous pregnancy loss within 10 weeks of gestation within 10 weeks of gestation
Secondary Late fetal loss Spontaneous pregnancy loss after 10 weeks of gestation after 10 weeks of gestation
Secondary Stillbirth Spontaneous pregnancy loss after 20 weeks of gestation after 20 weeks of gestation
Secondary Preterm delivery Live birth before 37 weeks of gestation between 28 and 37 weeks of gestation
Secondary Low-weight birth newborns with low weight (<2500g) after 28 weeks of gestation
Secondary Premature rupture of membranes the number of participants complicated with premature rupture of membranes after 28 weeks of gestation
Secondary Placental abruption the number of participants complicated with placental abruption after 28 weeks of gestation
Secondary Fetal growth retardation (FGR) weight below the 10th percentile for the gestational age after 12 weeks of gestation
Secondary Number of participants with low amniotic fluid during pregnancy the number of participants whose B-ultrasound indicates low amniotic fluid during pregnancy after 12 weeks of gestation
Secondary Number of participants with abnormal S / D values during pregnancy the number of participants whose B-ultrasound indicates abnormal S / D values during pregnancy after 12 weeks of gestation
Secondary Number of participants with placental hematoma during pregnancy the number of participants whose B-ultrasound indicates placental hematoma during pregnancy during pregnancy, an average of 10 months
Secondary Eclampsia New-onset hypertension after 20 weeks of gestation, with or without proteinuria > 300mg/24h, with or without any organ damage with seizures after 20 weeks of gestation
Secondary Gestational diabetes the number of participants who were diagnosed with gestational diabetes through study completion, an average of 10 months
Secondary Gestational hypertension the number of participants who were diagnosed with gestational hypertension through study completion, an average of 10 months
Secondary Number of participants with placental infarction the number of participants whose placenta with infarction. at delivery
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A